KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Operations (2016 - 2025)

Inovio Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 21573495.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 21.39% year-over-year to 21573495.0; the TTM value through Sep 2025 reached 88922790.0, up 19.66%, while the annual FY2024 figure was 104076553.0, 16.31% up from the prior year.
  • Cash from Operations for Q3 2025 was 21573495.0 at Inovio Pharmaceuticals, down from 20811359.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 19663909.0 in Q4 2024 and bottomed at 78459231.0 in Q2 2021.
  • The 5-year median for Cash from Operations is 32314656.0 (2023), against an average of 38401312.16.
  • The largest annual shift saw Cash from Operations tumbled 188.97% in 2021 before it soared 56.85% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 37891163.0 in 2021, then rose by 4.09% to 36340032.0 in 2022, then grew by 27.69% to 26275785.0 in 2023, then grew by 25.16% to 19663909.0 in 2024, then dropped by 9.71% to 21573495.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Cash from Operations are 21573495.0 (Q3 2025), 20811359.0 (Q2 2025), and 26874027.0 (Q1 2025).